Thursday, February 19, 2009

Landmark Trial Provides Vital Information for Cardiac Disease Treatment

Landmark Trial Provides Vital Information for Cardiac Disease Treatment

NorthShore University HealthSystem Ted Feldman, M.D., Lead Investigator

Evanston, IL. -- NorthShore University HealthSystem (http://www.northshore.org/) (NorthShore) has played a leading role in a landmark clinical trial comparing two forms of treatment for patients with severe coronary artery disease (CAD). The results were published on-line in this week's issue of the New England Journal of Medicine.

The SYNTAX trial was a clinical research study that compared percutaneous coronary intervention (PCI) with drug-eluting stents and coronary artery bypass surgery (CABG) in patients with three-vessel and left main coronary disease. The trial results did not show any statistically significant differences between PCI and CABG in rates of death or heart attack, an excess of stroke in the CABG treated patients, and a greater need for repeat PCI procedures in the stent treated patients. These are better outcomes for PCI than have been seen in prior trials in less complex patients.

"At NorthShore, we experienced stunning outcomes in patients whose only option would have previously been bypass surgery," said Ted Feldman, M.D, F.S.C.A.I., Director of Cardiac Catheterization Laboratory, NorthShore University HealthSystem, and a lead investigator of the trial. "The data in this study will provide cardiologists with additional information as they determine treatment therapy for patients with complex CAD."

The trial is the first randomized, controlled clinical trial to compare these two treatments in patients with left main disease and/or three-vessel disease, who are typically treated with CABG and represent a population with far more complex anatomy and advanced disease than those studied in prior drug-eluting stent (DES) clinical trials.

There were 1,800 patients enrolled in the randomized arm of the trial. All patients were assessed by a multidisciplinary team including an interventional cardiologist and a cardiac surgeon. If both the cardiologist and surgeon felt that they could offer equivalent complete revascularization, patients were randomized 1:1 into one of the two treatment strategies. If either the cardiologist or surgeon felt that one or the other revascularization technique was the preferred option, due to technical considerations or co-morbidity, for example, then patients were recruited into one of two parallel, nested registries for PCI or CABG. Thus, patients in the PCI registry had been rejected for cardiac surgery.

About NorthShore University HealthSystem

Headquartered in Evanston, Ill., NorthShore University HealthSystem (NorthShore) is a comprehensive, fully integrated, healthcare delivery system that serves the greater North Shore and northern Illinois communities. The system includes three Hospitals--Evanston Hospital, Glenbrook Hospital and Highland Park Hospital--and a fourth, Skokie-based Rush North Shore Hospital, to be added in January 2009. In addition, the healthsystem has more than 2,000 affiliated physicians, including a 550-physician, multispecialty physician group practice with over 70 office locations-- NorthShore University HealthSystem Medical Group. Further, NorthShore is committed to excellence in its academic mission and supports teaching and research as the principal teaching affiliate of the University of Chicago's Pritzker School of Medicine. The NorthShore University HealthSystem Research Institute, with more than $100 million of grants, focuses on clinical and translational research, including leadership in outcomes research and clinical trials.

NorthShore has annual revenues of $1.5 billion and a staff of more than 8,000. The healthsystem has significant capabilities in a wide spectrum of clinical programs, including cancer, heart, orthopaedics, high-risk maternity and pediatrics. NorthShore is a national leader in the implementation of innovative technologies, including electronic medical records, (EMR ). In 2003, the healthsystem was among the first in the country to successfully launch a systemwide EMR with demonstrable benefits in quality, safety, efficiency and service to patients. NorthShore has been recognized by multiple national organizations for this notable achievement. Visit http://www.northshore.org/

CONTACT: Amy Ferguson

Senior Director, Public Relations

NorthShore University HealthSystem

(847) 570-3146

###



Contact Information Amy Ferguson

Northshore University HealthSystem

http://www.northshore.org/

847-570-3146



Wednesday, February 18, 2009

Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy

Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy

CardioCareLive, a medical conference that takes place entirely online, announces participation of Dr. Larry Kaskel, Founder and Medical Director of the Heart Attack Prevention Center. Dr. Kaskel to present "Improved Patient Outcomes and Enhanced Revenue with Therapeutic Lifestyle Changes."

Needham, MA (PRWEB) February 18, 2009 -- CardioCareLive (http://www.cardiocarelive.com), the first of its kind online medical conference for primary care physicians and other healthcare professionals who work with patients with cardiometabolic risk factors, today announced Metagenics as an exhibitor at the March 3-4 event. Metagenics will also sponsor a session by Dr. Larry Kaskel, Founder and Medical Director of the Heart Attack Prevention Center, who will speak on "Improved Patient Outcomes and Enhanced Revenue with Therapeutic Lifestyle Changes." Attendees can watch this live video session and have their questions addressed in near real-time by Dr. Kaskel.

CardioCareLive provides an opportunity for healthcare practitioners to learn and interact with leading practitioners and stay informed about new treatments and therapies for patients with cardiovascular risk factors, such as Metagenics' FirstLine Therapy® program. This turn-key therapeutic lifestyle change program is easy to integrate into a practice and enables primary care physicians to provide lifestyle change therapies in a systematic way that is successful for the patient while also a revenue driver for the practice.

"Physicians recognize the need to guide their patients through lifestyle changes in order to achieve better outcomes," said Mike Katke, VP of Medical Marketing for Metagenics. "But time constraints and practice processes make ongoing care of this type challenging. FirstLine Therapy provides a systematic approach to aid patients in implementing lifestyle changes that can be truly successful."

CardioCareLive recognizes the need for time-constrained physicians to stay current with the latest healthcare innovations. The event delivers all the benefits of a physical medical conference, with live keynote presentations, lectures, peer networking and an exhibit floor, from the convenience of a computer. To view a complete list of speakers, agenda, or to register now for free, visit CardioCarelive.com (http://www.CardioCareLive.com).

About CardioCareLive

CardioCareLive, a medical conference that takes place entirely online, enables healthcare practitioners and others interested in understanding and managing cardiometabolic risk factors to learn, connect and interact through powerful Web-based software and services.

CardioCareLive is produced by PlatformQ (http://www.platformq.com), whose mission is to connect people, companies, organizations and associations worldwide to meet, interact and learn from leading experts and thought leaders through proven interactive tools at online events.

CardioCareLive and PlatformQ are trademarks of PlatformQ, LLC. All other trademarks or service marks are property of their respective owners.

About Metagenics

Metagenics, Inc. (http://www.metagenics.com) is a life sciences company and the premier manufacturer and distributor of science-based medical foods, nutraceuticals and therapeutic lifestyle change programs marketed to healthcare professionals. As a leader in the fields of nutrigenomics and functional medicine, healthcare practitioners around the world rely on Metagenics' products and services to help their patients achieve a lifetime of good health.

Press Contact: Sal Giliberto, 617-938-6006.

###



Contact Information Martha Collins

PlatformQ, LLC.

http://www.CardioCareLive.com

(617) 938-6008